Empirical examination of the neutrophil criterion (>1500 μl-1) currently needed to declare CR in AML

Elihu Estey, Francis Giles, Jorge Cortes, Miloslav Beran, Srdan Verstovsek, Guillermo Garcia-Manero, Stefan Faderl, Hagop Kantarjian

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Currently, NCI guidelines require that the neutrophil count exceed 1500 before complete remission (CR) may be declared in acute myeloid leukemia (AML). We tested the empirical validity of this formulation by comparing event-free survival (EFS) in CR in (a) 305 patients who met the NCI criteria for CR and (b) 36 patients who met all the criteria for CR except that the neutrophil count at what we considered CR was 1000-1499 (lower neutrophil group) at which time they began post-remission therapy. EFS was statistically identical in both groups. We extended these findings to 752 patients, who met the NCI criteria for CR except that some may have had circulating blasts at "CR"; 82 of the 752 were in the lower neutrophil group. These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalLeukemia Research
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 1 2003
Externally publishedYes

    Fingerprint

Keywords

  • 1000 neutrophils
  • 1500 neutrophils
  • AML
  • CR
  • NCI criteria

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this